Components
Community claim
Weight reduction through amylin and GLP-1 pathways.
Community and market provenance
Community mention, not clinical evidence
- Source: pdf01 · Page 2
- Source: pdf04 · Page 9
- Source: pdf05 · Page 2
- Source: pdf06 · Page 4
- Source: pdf07 · Page 3
- Source: img07 · Page 1
- Source: img09 · Page 1
Evidence of the exact combination
REDEFINE-1 randomized phase 3 trial provides direct evidence for the studied cagrilintide–semaglutide regimen. This is stronger than ingredient-only reasoning but does not validate an unverified CagriSema-labeled vial.
Component links are not combination evidence. A commercial name’s composition may vary.
Uncertainty and risks
Trial-specific formulation and monitoring do not validate supplier premixes; gastrointestinal burden and product identity remain material.
Observed in supplier/community material; prevalence not quantified.
No dosing or mixing instructions are provided.
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-WEG
October 16, 2026
- PMID33567185
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group.
October 16, 2026
- PMID40544433
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group.
October 16, 2026
- R30
- REG-WEG
October 16, 2026
- SEARCH-PUBMED-cagrilintide
PubMed/MED targeted search: TITLE:"cagrilintide" AND TITLE:phase
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026